BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Ikena Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:47 am Purchase | 2023-12-31 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND L P | 4,769,164 9.900% | 2,266,093 (+90.53%) | Filing |
| 2023-02-13 6:11 pm Purchase | 2022-12-31 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND L P | 2,503,071 6.900% | 704,700 (+39.19%) | Filing |
| 2022-02-14 1:35 pm Purchase | 2021-12-31 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND L P | 1,798,371 5.000% | 198,713 (+12.42%) | Filing |
| 2021-04-05 5:03 pm Purchase | 2021-03-26 | 13G | Ikena Oncology, Inc. IKNA | BIOTECHNOLOGY VALUE FUND L P | 1,599,658 5.100% | 1,599,658 (New Position) | Filing |